Expression of hypoxia-inducible factor-1 alpha and 2 alpha in advanced breast cancer after neoadjuvant therapy

Septelia Inawati Wanandi, Cahya Candra, Syarifah Dewi, Ramadan Karsono

Research output: Contribution to journalArticlepeer-review

Abstract

Advanced breast cancer may aggressively progress under hypoxic conditions, leading to therapy resistance and metastasis, and the effects of neoadjuvant therapy on tumor hypoxia remain unclear. The current study aimed to evaluate the expressions of hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible factor-2 alpha (HIF-2α) in advanced breast cancer cells following neoadjuvant treatment and their correlation with clinical characteristics. In total, 48 breast cancer specimens were collected before and after neoadjuvant therapy (28 treated with chemotherapy, 20 with hormonal therapy). Total RNA was isolated from 50 mg specimens. The mRNA levels of HIF-1α and HIF-2α were measured using qRT-PCR. The 18S rRNA was used as housekeeping gene. This study demonstrates that HIF-2α mRNA expression was significantly lower than those before therapy, whereas that of HIF-1α remained unchanged. We categorized the data based on clinical characteristics, and found that the increased expression of HIF-1α was associated with reduced patient survival. Moreover, high expressions of HIF-1α and HIF-2α were found in patients aged > 40 years having breast cancer of low histopathological grades. Thus, we conclude that high expressions of HIF-1α and HIF-2α may be used as biomarkers for the prediction of patient survival following neoadjuvant therapy in advanced breast cancer.

Original languageEnglish
Pages (from-to)247-253
Number of pages7
JournalJournal of International Dental and Medical Research
Volume12
Issue number1
Publication statusPublished - 1 Jan 2019

Keywords

  • Advanced breast cancer
  • HIF-1α
  • HIF-2α
  • Neoadjuvant therapy

Fingerprint Dive into the research topics of 'Expression of hypoxia-inducible factor-1 alpha and 2 alpha in advanced breast cancer after neoadjuvant therapy'. Together they form a unique fingerprint.

Cite this